BR112017007545A2 - derivados de carbazol - Google Patents

derivados de carbazol

Info

Publication number
BR112017007545A2
BR112017007545A2 BR112017007545A BR112017007545A BR112017007545A2 BR 112017007545 A2 BR112017007545 A2 BR 112017007545A2 BR 112017007545 A BR112017007545 A BR 112017007545A BR 112017007545 A BR112017007545 A BR 112017007545A BR 112017007545 A2 BR112017007545 A2 BR 112017007545A2
Authority
BR
Brazil
Prior art keywords
compounds
carbazole derivatives
diseases
btk
slowing
Prior art date
Application number
BR112017007545A
Other languages
English (en)
Portuguese (pt)
Inventor
G Batt Douglas
E Macor John
A Tino Joseph
Liu Qingjie
Ahmad Saleem
Kesavan Nair Satheesh
Hunter Watterson Scott
Kumar Maishal Tarun
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017007545(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112017007545A2 publication Critical patent/BR112017007545A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
BR112017007545A 2014-10-24 2015-10-23 derivados de carbazol BR112017007545A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (1)

Publication Number Publication Date
BR112017007545A2 true BR112017007545A2 (pt) 2017-12-19

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017007545A BR112017007545A2 (pt) 2014-10-24 2015-10-23 derivados de carbazol

Country Status (34)

Country Link
US (3) US10266491B2 (enExample)
EP (1) EP3209651B9 (enExample)
JP (1) JP6599983B2 (enExample)
KR (1) KR102514914B1 (enExample)
CN (1) CN107074804B (enExample)
AR (1) AR102427A1 (enExample)
AU (1) AU2015335703B2 (enExample)
BR (1) BR112017007545A2 (enExample)
CA (1) CA2965523A1 (enExample)
CL (1) CL2017001001A1 (enExample)
CO (1) CO2017004517A2 (enExample)
CY (1) CY1122549T1 (enExample)
DK (1) DK3209651T3 (enExample)
EA (1) EA032361B1 (enExample)
ES (1) ES2761903T3 (enExample)
HR (1) HRP20192197T2 (enExample)
HU (1) HUE048321T2 (enExample)
IL (1) IL251798B (enExample)
LT (1) LT3209651T (enExample)
MA (1) MA40302B1 (enExample)
ME (1) ME03754B (enExample)
MX (1) MX374724B (enExample)
MY (1) MY190568A (enExample)
PE (1) PE20171239A1 (enExample)
PH (1) PH12017500724B1 (enExample)
PL (1) PL3209651T3 (enExample)
PT (1) PT3209651T (enExample)
RS (1) RS59707B1 (enExample)
SG (2) SG11201703187PA (enExample)
SI (1) SI3209651T1 (enExample)
SM (1) SMT202000035T1 (enExample)
TN (1) TN2017000158A1 (enExample)
TW (1) TWI676618B (enExample)
WO (1) WO2016065236A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201903621SA (en) * 2014-10-24 2019-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds
HRP20210320T1 (hr) 2014-10-24 2021-04-30 Takeda Pharmaceutical Company Limited Spojevi heteroarila za liječenje oftalmičkih bolesti
CN109153680B (zh) * 2016-07-07 2021-04-23 株式会社大熊制药 4-氨基吡唑并[3,4-d]嘧啶基氮杂双环衍生物及含其的药物组合物
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2019075386A1 (en) 2017-10-13 2019-04-18 The Regents Of The University Of California MODULATORS OF MTORC1
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
WO2021067657A1 (en) * 2019-10-04 2021-04-08 Bristol-Myers Squibb Company Substituted carbazole compounds
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H,6H)-二酮类化合物的合成方法
AU2021253584A1 (en) * 2020-04-10 2022-11-17 Gb005, Inc. Kinase inhibitors
WO2021247748A1 (en) * 2020-06-02 2021-12-09 Gb005, Inc. Kinase inhibitors
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
WO2024010784A1 (en) * 2022-07-06 2024-01-11 Vividion Therapeutics, Inc. Pharmaceutical compositions comprising wrn helicase inhibitors
CN120530096A (zh) * 2022-09-29 2025-08-22 维维迪昂疗法有限公司 作为keap1调节剂的n-丙烯酰吗啉衍生物及其用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
KR20070119606A (ko) 2004-11-10 2007-12-20 씨지아이 파마슈티칼스, 인크. 특정 이미다조[1,2-a]피라진-8-일아민, 그의 제조 방법및 용도
AU2005315319B2 (en) 2004-12-17 2011-07-07 Glenmark Pharmaceuticals S.A. Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
ES2390135T3 (es) * 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
SG174810A1 (en) 2006-09-11 2011-10-28 Matrix Lab Ltd Dibenzofuran derivatives as inhibitors of pde-4 and pde-10
US20100160292A1 (en) 2006-09-11 2010-06-24 Cgi Pharmaceuticals, Inc Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
CA2707491A1 (en) 2007-12-13 2009-06-18 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
JP2011512354A (ja) 2008-02-14 2011-04-21 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経機能障害を検知するための新規の造影剤
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
JP2011524893A (ja) 2008-06-18 2011-09-08 ファイザー・リミテッド ニコチンアミド誘導体
US8450335B2 (en) 2008-06-27 2013-05-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
CN102325753B (zh) * 2008-12-19 2014-09-10 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
WO2010093949A2 (en) 2009-02-13 2010-08-19 Nextivity, Inc. Remote control for booster
WO2011159857A1 (en) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
WO2012066442A1 (en) 2010-11-15 2012-05-24 Pfizer Limited Inhibitors of hiv replication
KR101585753B1 (ko) 2011-05-17 2016-01-14 에프. 호프만-라 로슈 아게 브루톤 티로신 키나아제의 억제제
AU2013207972B2 (en) 2012-01-10 2017-06-15 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
JP6139690B2 (ja) 2012-10-26 2017-05-31 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ブルートンチロシンキナーゼの阻害剤
TWI648272B (zh) * 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
US9714234B2 (en) * 2013-06-25 2017-07-25 Bristol-Myers Squibb Company Carbazole carboxamide compounds
DK3461821T3 (da) 2014-10-24 2020-08-17 Bristol Myers Squibb Co Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
SG10201903621SA (en) * 2014-10-24 2019-05-30 Bristol Myers Squibb Co Tricyclic atropisomer compounds

Also Published As

Publication number Publication date
IL251798B (en) 2020-08-31
CL2017001001A1 (es) 2017-11-24
HRP20192197T1 (hr) 2020-03-06
CN107074804A (zh) 2017-08-18
PT3209651T (pt) 2019-12-30
LT3209651T (lt) 2020-01-10
TN2017000158A1 (en) 2018-10-19
IL251798A0 (en) 2017-06-29
MA40302B1 (fr) 2018-10-31
ME03754B (me) 2021-04-20
HRP20192197T2 (hr) 2020-11-13
DK3209651T3 (da) 2020-02-03
EP3209651B1 (en) 2019-10-23
CY1122549T1 (el) 2021-01-27
TWI676618B (zh) 2019-11-11
SG10201903619YA (en) 2019-05-30
JP6599983B2 (ja) 2019-10-30
AU2015335703A1 (en) 2017-06-08
CA2965523A1 (en) 2016-04-28
MX2017005255A (es) 2017-08-18
US11053197B2 (en) 2021-07-06
AU2015335703B2 (en) 2020-05-21
KR102514914B1 (ko) 2023-03-27
EA201790745A1 (ru) 2017-08-31
MY190568A (en) 2022-04-27
SI3209651T1 (sl) 2019-12-31
HRP20192197T8 (hr) 2020-04-03
EP3209651B9 (en) 2020-05-20
WO2016065236A1 (en) 2016-04-28
SG11201703187PA (en) 2017-05-30
MA40302A1 (fr) 2018-05-31
US20200255377A1 (en) 2020-08-13
CO2017004517A2 (es) 2017-08-31
TW201629014A (zh) 2016-08-16
MX374724B (es) 2025-03-06
CN107074804B (zh) 2020-02-18
KR20170075756A (ko) 2017-07-03
US10676434B2 (en) 2020-06-09
PE20171239A1 (es) 2017-08-24
PH12017500724A1 (en) 2017-10-09
PH12017500724B1 (en) 2023-07-05
PL3209651T3 (pl) 2020-03-31
US20170362176A1 (en) 2017-12-21
JP2017535536A (ja) 2017-11-30
HUE048321T2 (hu) 2020-07-28
AR102427A1 (es) 2017-03-01
US10266491B2 (en) 2019-04-23
EP3209651A1 (en) 2017-08-30
RS59707B1 (sr) 2020-01-31
SMT202000035T1 (it) 2020-03-13
US20190225583A1 (en) 2019-07-25
ES2761903T3 (es) 2020-05-21
EA032361B1 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
BR112017007545A2 (pt) derivados de carbazol
PH12020500265A1 (en) Indole carboxamides compounds useful as kinase inhibitors
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
MX391981B (es) Derivados de benzooxazol como inmunomoduladores.
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
NZ733174A (en) Quinazoline derivatives used to treat hiv
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
MX387097B (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
WO2016109217A3 (en) Btk inhibitors
MX390051B (es) Antagonistas de ep4.
AR101414A1 (es) Derivados de pirrolidinona como inhibidores de metap-2
EA201790870A1 (ru) Трициклические атропоизомерные соединения
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
CR20180091A (es) 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del vih
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
MX2018012223A (es) Formulaciones liquidas de fosfaplatino.
MX2019000159A (es) Pirrolo[2,3-d]piridazin-4-onas sustituidas y pirazolo[3,4-d]pirida zin-4-onas como inhibidores de la proteina quinasa.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]